Information Provided By:
Fly News Breaks for March 21, 2017
LMAT
Mar 21, 2017 | 07:06 EDT
First Analysis analyst Joseph Munda started LeMaitre with an Overweight rating and $29 price target, saying he expects the maker of peripheral vascular disease treatments to grow revenue at an 8-10% annual rate organically with additional growth from acquisitions and strong profitability.
News For LMAT From the Last 2 Days
There are no results for your query LMAT